Karyopharm Therapeutics (KPTI) Cash from Investing Activities (2013 - 2025)

Karyopharm Therapeutics has reported Cash from Investing Activities for 13 years, with the latest figure at $5.0 million in Q4 2025.

• For the quarter ending Q4 2025, Cash from Investing Activities fell 66.21% year-over-year to $5.0 million; the trailing twelve-month figure through Dec 2025 stood at $43.4 million (down 54.57% YoY), and the FY2025 full-year result was $43.4 million, down 54.57% from the prior year.
• Cash from Investing Activities for Q4 2025 stood at $5.0 million, up from $4.8 million in the prior quarter.
• The five-year high for Cash from Investing Activities was $51.3 million in Q2 2024, with the low at -$65.3 million in Q4 2022.
• Historically, Cash from Investing Activities has averaged $9.2 million across 5 years, with a median of $15.0 million in 2024.
• Annual changes were most pronounced in 2022 — Cash from Investing Activities tumbled 312.21% — and 2024, when it jumped 197.25%.
• Karyopharm Therapeutics' Cash from Investing Activities stood at $30.8 million in 2021, then tumbled by 312.21% to -$65.3 million in 2022, then soared by 141.11% to $26.8 million in 2023, then tumbled by 44.88% to $14.8 million in 2024, then tumbled by 66.21% to $5.0 million in 2025.
• The last three Cash from Investing Activities figures came in at $5.0 million (Q4 2025), $4.8 million (Q3 2025), and $18.3 million (Q2 2025), per Business Quant data.